Skip to main content

Table 2 Characteristics and findings of included studies

From: A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments

Care Location Year Country Design Intervention Comparator Number of participants Uptake (%) SVR (%)
Primary Care         
Bloom 2017 Australia Prospective cohort study of treatment uptake and SVR Adherence to DAA treatment protocols Treatment by tertiary care provider 1044 503 (40.6) 253 (50.2)
Francheville 2017 Canada Prospective observational study design Specialist nurse-led care No comparator group 242 93 (38.4) 82 (88.2)
Kattakuzhy 2017 USA Non-randomised open label study Treatment by primary care providers (PCP) and nurse practitioners (NP) Standard care - Treatment by secondary care clinic NP 150 PCP 160   NP 134 (89.3) PCP139(86.9)
McCLure 2017 Australia Retrospective data analysis of SVR12 Nurse-led care and GP remote consultation Specialist care in Tertiary centre Nurse-led 70 50 (74.3) 46 (65.7)
Miller 2016 USA Retrospective observational study Treatment by primary care providers No comparator group 95   79 (83)
Norton 2017 USA Retrospective cohort study of SVR Treatment in urban primary care centre SVR 12 in PWIDs and non_PWIDs 89   85(95.5)
Wade 2018 Australia Randomised controlled trial Testing, assessment and treatment in primary care Testing, assessment and treatment in tertiary care 59 31 (52.5) 14 (23.7)
Integrated Health Systems (ECHO)         
Abdulameer 2016 USA Retrospective data analysis of SVR 12 VA-Echo model supporting primary care providers No comparator group 588   318 (54)
Beste 2017 USA Retrospective cohort study of treatment uptake and SVR VA-Echo model supporting primary care providers Standard care - Treatment by unexposed primary care providers 6431 1303 (21.4) (58.2)
Buchanan 2015 United Kingdom Retrospective data analysis Community-based outreach clinic Standard care - Treatment by secondary care clinic 77 24 (31.2)  
Georgie 2016 USA Retrospective data analysis of SVR12 VA-Echo model supporting primary care providers Treatment by sub-specialist providers 623   Genotype 1 (GT1) (99) GT2 (98) GT3 (79)
Opioid Treatment Centres         
Butner 2017 USA Retrospective data analysis Opioid treatment programme No comparator group 75 75.0 64 (85.0)
Morris 2017 Australia Retrospective data analysis of treatment uptake and SVR Treatment in a community-based harm reduction and treatment facility No comparator group 127 122 (96) 102 (80.3)
Read 2017 Australia Retrospective data analysis of SVR12 Treatment of PWIDs in primary care setting No comparator group 72   59 (81.9)
Pharmacies / Pharmacist Clinics         
David 2017 USA Retrospective data analysis of SVR12 Pharmacy-managed clinics Treatment by non-pharmacist providers 204   (83.6)
Radley 2017 United Kingdom Pilot cluster RCT of treatment uptake and SVR Treatment in community Pharmacy Treatment by secondary care clinic 26 3 (11.5) 3 (11.5)
Telemedicine         
Cooper 2017 Canada Retrospective cohort study of treatment uptake and SVR Use of telemedicine Treatment by secondary care clinic 157 35.0 18 (11.5)